StockNews.com Downgrades Voyager Therapeutics (NASDAQ:VYGR) to Hold

Voyager Therapeutics (NASDAQ:VYGR) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday.

A number of other analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Voyager Therapeutics in a research note on Thursday. Wedbush lowered their price objective on shares of Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a research note on Wednesday, August 7th. Leerink Partners assumed coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 target price on the stock. Finally, Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a research report on Wednesday, October 16th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $17.43.

Voyager Therapeutics Stock Up 2.7 %

NASDAQ:VYGR opened at $6.75 on Friday. The stock has a market capitalization of $367.16 million, a price-to-earnings ratio of -135.00 and a beta of 0.91. Voyager Therapeutics has a 52 week low of $5.71 and a 52 week high of $11.72. The firm has a 50 day moving average of $6.55 and a 200 day moving average of $7.61.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.20. Voyager Therapeutics had a return on equity of 3.31% and a net margin of 6.28%. The firm had revenue of $29.58 million during the quarter, compared to analysts’ expectations of $11.52 million. During the same quarter last year, the firm earned ($0.51) EPS. As a group, analysts expect that Voyager Therapeutics will post -1.27 EPS for the current year.

Insider Buying and Selling at Voyager Therapeutics

In other news, insider Sandell Jacquelyn Fahey sold 5,999 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the sale, the insider now owns 86,001 shares in the company, valued at $500,525.82. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.53% of the company’s stock.

Institutional Trading of Voyager Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Armistice Capital LLC boosted its stake in shares of Voyager Therapeutics by 11.3% during the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock worth $41,132,000 after acquiring an additional 528,000 shares in the last quarter. Vanguard Group Inc. boosted its position in Voyager Therapeutics by 27.8% during the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock worth $30,087,000 after purchasing an additional 702,030 shares in the last quarter. Farallon Capital Management LLC boosted its position in Voyager Therapeutics by 77.4% during the first quarter. Farallon Capital Management LLC now owns 2,292,000 shares of the company’s stock worth $21,339,000 after purchasing an additional 1,000,000 shares in the last quarter. Great Point Partners LLC acquired a new stake in Voyager Therapeutics in the second quarter valued at approximately $12,668,000. Finally, Price T Rowe Associates Inc. MD increased its position in shares of Voyager Therapeutics by 3.7% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after buying an additional 37,144 shares in the last quarter. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.